Ameliorative effect of orally administered different linoleic acid/α-linolenic acid ratios in a mouse model of DNFB-induced atopic dermatitis

Li, Xiaolei; Wan, Liping; Wang, Huiling; Mai, Qianting; Deng, Zixin; Ding, Hong

doi:10.1016/j.jff.2019.103754

Cited by 16 publications

(9 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Skin swelling, typically as a result of inflammation or fluid retention in the skin, is an indicator of skin edema. 21 , 22 In this study, skin edema was evaluated by comparing the difference in the thickness/weight among different groups. As shown in Figures 6D and E , the dorsal skin thickness and skin weight were gradually elevated in DNFB-treated AD mice.…”

Section: Resultsmentioning

confidence: 99%

Molecular Mechanisms of Luteolin Against Atopic Dermatitis Based on Network Pharmacology and in vivo Experimental Validation

Gao¹,

Li²,

Cao³

et al. 2022

DDDT

Self Cite

View full text Add to dashboard Cite

Purpose To undercover the underlying mechanisms of luteolin against atopic dermatitis (AD), clinically characterized by recurrent eczematous lesions and intense itching, based on network pharmacology, molecular docking and in vivo experimental validation. Methods TCMSP, STITCH and SwissTargetPrediction databases were utilized to screen the corresponding targets of luteolin. Targets related to AD were collected from DisGeNET, GeneCards and TTD databases. PPI network of intersection targets was constructed through STRING 11.0 database and Cytoscape 3.9.0 software. GO and KEGG enrichment analysis were performed to investigate the critical pathways of luteolin against AD. Further, the therapeutic effects and candidate targets/signaling pathways predicted from network pharmacology analysis were experimentally validated in a mouse model of AD induced by 2, 4-dinitrofluorobenzene (DNFB). Results A total of 31 intersection targets were obtained by matching 151 targets of luteolin with 553 targets of AD. Among all, 20 core targets were identified by PPI network topology analysis, including IL-6, TNF, IL-10, VEGFA, IL-4, etc., and molecular docking indicated that luteolin binds strongly to these core targets. KEGG pathway enrichment analysis suggested that the intersected targets were significantly enriched in IL-17 signaling pathway, Th17 cell differentiation, Th1 and Th2 cell differentiation, JAK/STAT signaling pathway, etc. The in vivo experiment validated that luteolin could alleviate AD-like skin symptoms, as evidenced by the lower SCORAD score, the reduced infiltration of mast cells and the recovery of skin barrier function. Furthermore, luteolin restored immune balance by regulating the production of Th1/Th2/Th17-mediated cytokines, which were both the predicted core targets. Moreover, luteolin inhibited the phosphorylation of JAK2 and STAT3 in the lesional skin. Conclusion Together, the present study systematically clarifies the ameliorative effects and possible molecular mechanisms of luteolin against AD through the combination of network pharmacology and experimental validation, shedding light on the future development and clinical application of luteolin.

show abstract

Section: Resultsmentioning

confidence: 99%

Molecular Mechanisms of Luteolin Against Atopic Dermatitis Based on Network Pharmacology and in vivo Experimental Validation

Gao¹,

Li²,

Cao³

et al. 2022

DDDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Administration of LA/ALA also inhibited the proliferation and infiltration of T cells, the production of Th1, Th2, and Th17 cytokines in dorsal skin and serum of DNFB‐treated mice. Moreover, LA/ALA downregulated the protein expressions of JAK2 and STAT4, and thus reducing the synthesis of type Th1 cytokine IFN‐γ (Tang et al, 2020). The findings suggest the beneficial effects of optimal nutrition ratio of LA/ALA on atopic dermatitis‐like symptoms, which provide a theoretical basis for its therapeutic potential in the clinical prevention and treatment of atopic dermatitis.…”

Section: Resultsmentioning

confidence: 99%

Experimental and clinical studies on the effects of Portulaca oleracea L. and its constituents on respiratory, allergic, and immunologic disorders, a review

Khazdair

Saadat

Aslani

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

Various pharmacological effects for Portulaca oleracea were shown in previous studies. Therefore, the effects of P. oleracea and its derivatives on respiratory, allergic, and immunologic diseases according to update experimental and clinical studies are provided in this review article. PubMed/Medline, Scopus, and Google Scholar were searched using appropriate keywords until the end of December 2020. The effects of P. oleracea and its constituents such as quercetin and kaempferol on an animal model of asthma were shown. Portulaca oleracea and its constituents also showed therapeutic effects on chronic obstructive pulmonary disease and chronic bronchitis in both experimental and clinical studies. The possible bronchodilatory effect of P. oleracea and its ingredients was also reported. Portulaca oleracea and its constituents showed the preventive effect on lung cancer and a clinical study showed the effect of P. oleracea on patients with lung adenocarcinoma. In addition, a various constituents of P. oleracea including, quercetin and kaempferol showed therapeutic effects on lung infections. This review indicates the therapeutic effect of P. oleracea and its constituents on various lung and allergic disorders but more clinical studies are required to establish the clinical efficacy of this plant and its constituents on lung and allergic disorders.

show abstract

“…In three sections, five different areas randomly selected were analyzed using ImageJ software for the ratio of protein immune-stained areas to the total area of epidermal immunestained areas. 12 The behavioral animal tests Mice were placed in their cages and taken to the behavioral laboratory where the temperature was controlled at 22 ± 2 °C and the behavioral laboratory was acoustically isolated from the rest of the room. The mice needed at least 2 h to acclimate to laboratory conditions before starting the experiment.…”

Section: Immuno-histochemical Stainingmentioning

confidence: 99%

Fructo‐oligofructose ameliorates 2,4‐dinitrofluorobenzene‐induced atopic dermatitis‐like skin lesions and psychiatric comorbidities in mice

et al. 2023

Self Cite

View full text Add to dashboard Cite

BACKGROUND Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by pruritus and eczema lesions and psychiatric comorbidities. The gut–brain–skin axis plays a pivotal role during AD development, which might suggest a novel therapeutic strategy for AD. The present study aims to uncover the protective effects and underlying mechanisms of fructo‐oligofructose (FOS), a type of prebiotic, on AD‐like skin manifestations and comorbid anxiety and depression in AD mice. RESULTS Female Kunming mice were treated topically with 2,4‐dinitrofluorobenzene (DNFB) to induce AD‐like symptoms and FOS was administered daily for 14 days. The results showed that FOS could alleviate AD‐like skin lesions markedly as evidenced by dramatic decreases in severity score, scratching bouts, the levels of immunoglobulin E (IgE) and T helper 1(Th1)/Th2‐related cytokines, and the infiltration of inflammatory cells and mast cells to the dermal tissues. The comorbid anxiety and depressive‐like behaviors, estimated by the forced swimming test (FST), the tail‐suspension test (TST), the open‐field test (OFT), and the zero maze test (ZMT) in AD mice, were significantly attenuated by FOS. Fructo‐oligofructose significantly upregulated brain neurotransmitters levels of 5‐hydroxytryptamine (5‐HT) and dopamine (DA). Furthermore, FOS treatment increased the relative abundance of gut microbiota, such as Prevotella and Lactobacillus and the concentrations of short‐chain fatty acids (SCFAs), especially acetate and iso‐butyrate in the feces of AD mice. The correlation analysis indicated that the reshaped gut microbiome composition and enhanced SCFAs formation are associated with skin inflammation and behavioral alteration. CONCLUSION Collectively, these data identify FOS as a promising microbiota‐targeted treatment for AD‐like skin inflammation and comorbid anxiety and depressive‐like behaviors. © 2023 Society of Chemical Industry.

show abstract

Ameliorative effect of orally administered different linoleic acid/α-linolenic acid ratios in a mouse model of DNFB-induced atopic dermatitis

Cited by 16 publications

References 68 publications

Molecular Mechanisms of Luteolin Against Atopic Dermatitis Based on Network Pharmacology and in vivo Experimental Validation

Molecular Mechanisms of Luteolin Against Atopic Dermatitis Based on Network Pharmacology and in vivo Experimental Validation

Experimental and clinical studies on the effects of Portulaca oleracea L. and its constituents on respiratory, allergic, and immunologic disorders, a review

Fructo‐oligofructose ameliorates 2,4‐dinitrofluorobenzene‐induced atopic dermatitis‐like skin lesions and psychiatric comorbidities in mice

Contact Info

Product

Resources

About